Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.
Keywords: Benefit-risk; Brighton Collaboration; CEPI; COVID-19; Peptide; Protein; Recombinant; Safety; Template; Vaccine.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.